One Hit in Hand, Alexion Tries to Repeat After $8.4 Billion Deal

  • Drugmaker expands rare-disease strategy through acquisitions
  • New treatment praised in medical journal before FDA decision

Alexion Pharmaceuticals Inc. made its name selling one drug, Soliris, to a tiny handful of patients around the world for hundreds of thousands of dollars a year each. It’s been a lucrative model -- one the company is now trying to prove was no fluke.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.